Selected research
Industry Research
Recombinant Coagulation Factors Industry Research Report 2026
Market perspective
The global Recombinant Coagulation Factors market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Recombinant Coagulation Factors market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Recombinant Coagulation Factors market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Recombinant Coagulation Factors market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Recombinant Coagulation Factors include Novo Nordisk A/S, Pfizer Inc., Bayer AG, Baxter International Inc., Octapharma AG, Kedrion S.P.A., Grifols International SA, CSL Ltd. and Biogen Idec. among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Recombinant Coagulation Factors market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Recombinant Coagulation Factors.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Recombinant Coagulation Factors Market by Company
Novo Nordisk A/S
Pfizer Inc.
Bayer AG
Baxter International Inc.
Octapharma AG
Kedrion S.P.A.
Grifols International SA
CSL Ltd.
Biogen Idec
Recombinant Coagulation Factors Segment by Type
Recombinant Factor VIII
Recombinant Factor IX
Von Willebrand Factor
Recombinant Coagulation Factors Segment by Application
Clinics
Hospitals
Research Organizations
Recombinant Coagulation Factors Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Coagulation Factors market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Recombinant Coagulation Factors and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Coagulation Factors.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Recombinant Coagulation Factors companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Recombinant Factor VIII
- Recombinant Factor IX
- Von Willebrand Factor
Applications
- Clinics
- Hospitals
- Research Organizations
Companies covered
- Novo Nordisk A/S
- Pfizer Inc.
- Bayer AG
- Baxter International Inc.
- Octapharma AG
- Kedrion S.P.A.
- Grifols International SA
- CSL Ltd.
- Biogen Idec
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Recombinant Coagulation Factors by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Recombinant Factor VIII
- 2.2.3 Recombinant Factor IX
- 2.2.4 Von Willebrand Factor
- 2.3 Recombinant Coagulation Factors by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Clinics
- 2.3.3 Hospitals
- 2.3.4 Research Organizations
- 2.4 Assumptions and Limitations
3 Recombinant Coagulation Factors Breakdown Data by Type
- 3.1 Global Recombinant Coagulation Factors Historic Market Size by Type (2021-2026)
- 3.2 Global Recombinant Coagulation Factors Forecasted Market Size by Type (2027-2032)
4 Recombinant Coagulation Factors Breakdown Data by Application
- 4.1 Global Recombinant Coagulation Factors Historic Market Size by Application (2021-2026)
- 4.2 Global Recombinant Coagulation Factors Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Recombinant Coagulation Factors Market Perspective (2021-2032)
- 5.2 Global Recombinant Coagulation Factors Growth Trends by Region
- 5.2.1 Global Recombinant Coagulation Factors Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Recombinant Coagulation Factors Historic Market Size by Region (2021-2026)
- 5.2.3 Recombinant Coagulation Factors Forecasted Market Size by Region (2027-2032)
- 5.3 Recombinant Coagulation Factors Market Dynamics
- 5.3.1 Recombinant Coagulation Factors Industry Trends
- 5.3.2 Recombinant Coagulation Factors Market Drivers
- 5.3.3 Recombinant Coagulation Factors Market Challenges
- 5.3.4 Recombinant Coagulation Factors Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Recombinant Coagulation Factors Players by Revenue
- 6.1.1 Global Top Recombinant Coagulation Factors Players by Revenue (2021-2026)
- 6.1.2 Global Recombinant Coagulation Factors Revenue Market Share by Players (2021-2026)
- 6.2 Global Recombinant Coagulation Factors Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Recombinant Coagulation Factors Head Office and Area Served
- 6.4 Global Recombinant Coagulation Factors Players, Product Type & Application
- 6.5 Global Recombinant Coagulation Factors Manufacturers Established Date
- 6.6 Global Recombinant Coagulation Factors Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Recombinant Coagulation Factors Market Size (2021-2032)
- 7.2 North America Recombinant Coagulation Factors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Recombinant Coagulation Factors Market Size by Country (2021-2026)
- 7.4 North America Recombinant Coagulation Factors Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Recombinant Coagulation Factors Market Size (2021-2032)
- 8.2 Europe Recombinant Coagulation Factors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Recombinant Coagulation Factors Market Size by Country (2021-2026)
- 8.4 Europe Recombinant Coagulation Factors Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Recombinant Coagulation Factors Market Size (2021-2032)
- 9.2 Asia-Pacific Recombinant Coagulation Factors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Recombinant Coagulation Factors Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Recombinant Coagulation Factors Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Recombinant Coagulation Factors Market Size (2021-2032)
- 10.2 South America Recombinant Coagulation Factors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Recombinant Coagulation Factors Market Size by Country (2021-2026)
- 10.4 South America Recombinant Coagulation Factors Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Recombinant Coagulation Factors Market Size (2021-2032)
- 11.2 Middle East & Africa Recombinant Coagulation Factors Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Recombinant Coagulation Factors Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Recombinant Coagulation Factors Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Novo Nordisk A/S
- 12.1.1 Novo Nordisk A/S Company Information
- 12.1.2 Novo Nordisk A/S Business Overview
- 12.1.3 Novo Nordisk A/S Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.1.4 Novo Nordisk A/S Recombinant Coagulation Factors Product Portfolio
- 12.1.5 Novo Nordisk A/S Recent Developments
- 12.2 Pfizer Inc.
- 12.2.1 Pfizer Inc. Company Information
- 12.2.2 Pfizer Inc. Business Overview
- 12.2.3 Pfizer Inc. Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.2.4 Pfizer Inc. Recombinant Coagulation Factors Product Portfolio
- 12.2.5 Pfizer Inc. Recent Developments
- 12.3 Bayer AG
- 12.3.1 Bayer AG Company Information
- 12.3.2 Bayer AG Business Overview
- 12.3.3 Bayer AG Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.3.4 Bayer AG Recombinant Coagulation Factors Product Portfolio
- 12.3.5 Bayer AG Recent Developments
- 12.4 Baxter International Inc.
- 12.4.1 Baxter International Inc. Company Information
- 12.4.2 Baxter International Inc. Business Overview
- 12.4.3 Baxter International Inc. Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.4.4 Baxter International Inc. Recombinant Coagulation Factors Product Portfolio
- 12.4.5 Baxter International Inc. Recent Developments
- 12.5 Octapharma AG
- 12.5.1 Octapharma AG Company Information
- 12.5.2 Octapharma AG Business Overview
- 12.5.3 Octapharma AG Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.5.4 Octapharma AG Recombinant Coagulation Factors Product Portfolio
- 12.5.5 Octapharma AG Recent Developments
- 12.6 Kedrion S.P.A.
- 12.6.1 Kedrion S.P.A. Company Information
- 12.6.2 Kedrion S.P.A. Business Overview
- 12.6.3 Kedrion S.P.A. Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.6.4 Kedrion S.P.A. Recombinant Coagulation Factors Product Portfolio
- 12.6.5 Kedrion S.P.A. Recent Developments
- 12.7 Grifols International SA
- 12.7.1 Grifols International SA Company Information
- 12.7.2 Grifols International SA Business Overview
- 12.7.3 Grifols International SA Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.7.4 Grifols International SA Recombinant Coagulation Factors Product Portfolio
- 12.7.5 Grifols International SA Recent Developments
- 12.8 CSL Ltd.
- 12.8.1 CSL Ltd. Company Information
- 12.8.2 CSL Ltd. Business Overview
- 12.8.3 CSL Ltd. Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.8.4 CSL Ltd. Recombinant Coagulation Factors Product Portfolio
- 12.8.5 CSL Ltd. Recent Developments
- 12.9 Biogen Idec
- 12.9.1 Biogen Idec Company Information
- 12.9.2 Biogen Idec Business Overview
- 12.9.3 Biogen Idec Revenue in Recombinant Coagulation Factors Business (2021-2026)
- 12.9.4 Biogen Idec Recombinant Coagulation Factors Product Portfolio
- 12.9.5 Biogen Idec Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst